Drug intelligence / Profile preview

LNP3693

Development stage: Phase 1
Lead developer: Lupin
Modality: Small Molecules
Administration: Parenteral

Overview

LNP3693 is an investigational small molecule drug that acts as a STING (Stimulator of Interferon Genes) agonist, designed for parenteral administration. It is being developed primarily for the treatment of advanced or metastatic solid tumors and lymphoma. As a STING agonist, LNP3693 activates innate immune pathways to promote anti-tumor immune responses, positioning it as a novel immuno-oncology therapy. The drug is in early clinical development, with Phase 1 trial data focusing on safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in cancer patients[1][2][4][7][11][12][13][14].

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on LNP3693.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNP3693.